

# Anjali Tiku Owens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7022645/publications.pdf>

Version: 2024-02-01

46  
papers

1,441  
citations

471509

17  
h-index

361022

35  
g-index

47  
all docs

47  
docs citations

47  
times ranked

2454  
citing authors

#	ARTICLE	IF	CITATIONS
1	Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 554-563.	1.7	4
2	Cardiovascular Characteristics of Patients with Genetic Variation in Desmoplakin (DSP). <i>Neurology International</i> , 2022, 12, 24-36.	0.5	6
3	Cardiovascular Genetics. <i>Medical Clinics of North America</i> , 2022, 106, 313-324.	2.5	1
4	End Stage Mitochondrial Cardiomyopathy and Heart Transplantation Due to Biallelic Pathogenic <i>c1qbp</i> Variants. <i>Circulation Genomic and Precision Medicine</i> , 2022, 15, CIRCGEN121003559.	3.6	2
5	Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction. <i>Cardiac Failure Review</i> , 2022, 8, e10.	3.0	0
6	Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database Study. <i>Cardiology and Therapy</i> , 2022, 11, 249-267.	2.6	5
7	Left Ventricular Hypertrophy and Hypertrophic Cardiomyopathy in Adult Solid Organ Transplant Recipients. <i>Transplantation Direct</i> , 2022, 8, e1279.	1.6	0
8	A Parallel Need for Cardiovascular Care for Female Carriers of Duchenne and Becker Muscular Dystrophy. <i>Journal of Cardiac Failure</i> , 2022, 28, 1235-1236.	1.7	2
9	Frequency, Penetrance, and Variable Expressivity of Dilated Cardiomyopathy-Associated Putative Pathogenic Gene Variants in UK Biobank Participants. <i>Circulation</i> , 2022, 146, 110-124.	1.6	25
10	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice. <i>JAMA Cardiology</i> , 2021, 6, 267.	6.1	22
11	Cardioprotection in Duchenne muscular dystrophy. <i>European Heart Journal</i> , 2021, 42, 1985-1987.	2.2	4
12	Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support. <i>Circulation: Heart Failure</i> , 2021, 14, e007957.	3.9	24
13	Pathogenic LMNA variants disrupt cardiac lamina-chromatin interactions and de-repress alternative fate genes. <i>Cell Stem Cell</i> , 2021, 28, 938-954.e9.	11.1	61
14	Reappraising Genes for Dilated Cardiomyopathy: Stepping Back to Move Forward. <i>Circulation</i> , 2021, 144, 20-22.	1.6	4
15	Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 330-343.	2.8	90
16	Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1818-1824.	30.7	51
17	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , 2021, 8, 5531-5541.	3.1	11
18	Coronavirus disease 2019 in heart transplant recipients: Risk factors, immunosuppression, and outcomes. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 926-935.	0.6	36

#	ARTICLE	IF	CITATIONS
19	Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2021, 42, 3932-3944.	2.2	43
20	Mental health disorders and emergency resource use and outcomes in ventricular assist device supported patients. <i>American Heart Journal</i> , 2021, 240, 11-15.	2.7	1
21	Exploring experiences of hypertrophic cardiomyopathy diagnosis, treatment, and impacts on quality of life among middle-aged and older adults: An interview study. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2021, 50, 788-793.	1.6	2
22	Inflammation and Immune Response in Arrhythmogenic Cardiomyopathy: State-of-the-Art Review. <i>Circulation</i> , 2021, 144, 1646-1655.	1.6	51
23	Clinical utility of surveillance and clinically prompted right heart catheterization in patients listed for heart transplantation. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 28-34.	1.7	0
24	A genome-first approach to aggregating rare genetic variants in LMNA for association with electronic health record phenotypes. <i>Genetics in Medicine</i> , 2020, 22, 102-111.	2.4	42
25	Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. <i>Nature Communications</i> , 2020, 11, 163.	12.8	466
26	Advances in the Genetics and Genomics of Heart Failure. <i>Current Cardiology Reports</i> , 2020, 22, 132.	2.9	9
27	Clinical and procedural characteristics predicting need for chronotropic support and permanent pacing post-heart transplantation. <i>Heart Rhythm</i> , 2020, 17, 1132-1138.	0.7	5
28	Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, 458-485.	3.6	39
29	From Hypertrophy to Heart Failure: What Is New in Genetic Cardiomyopathies. <i>Current Heart Failure Reports</i> , 2019, 16, 157-167.	3.3	9
30	Good Intentions Gone Bad. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002560.	3.6	0
31	Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. <i>Circulation</i> , 2019, 140, 31-41.	1.6	195
32	Antepartum Diagnosis and Management of Lamin A/C Disease. <i>Case Reports in Cardiology</i> , 2019, 2019, 1-6.	0.2	0
33	Baseline Characteristics of the VANISH Cohort. <i>Circulation: Heart Failure</i> , 2019, 12, e006231.	3.9	10
34	Pulmonary hypertension: Barrier or just a bump in the road in transplanting adults with congenital heart disease. <i>Congenital Heart Disease</i> , 2018, 13, 492-498.	0.2	2
35	Reversal of Pacing-Induced Cardiomyopathy Following Cardiac Resynchronization Therapy. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 168-177.	3.2	70
36	Functional Annotation of TNNT2 Variants of Uncertain Significance With Genome-Edited Cardiomyocytes. <i>Circulation</i> , 2018, 138, 2852-2854.	1.6	32

#	ARTICLE	IF	CITATIONS
37	<i>&lt;i&gt;ACTA1&lt;/i&gt; Novel Likely Pathogenic Variant in a Family With Dilated Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, e002243.</i>	3.6	12
38	Decoding Dysfunction in Duchenne Muscular Dystrophy Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, e002051.	3.6	2
39	Pregnancy in hypertrophic cardiomyopathy. European Heart Journal, 2017, 38, 2691-2692.	2.2	4
40	Recreational Exercise in Hypertrophic Cardiomyopathy. JAMA - Journal of the American Medical Association, 2017, 317, 1319.	7.4	1
41	Neprilysin Inhibitors: Emerging Therapy for Heart Failure. Annual Review of Medicine, 2017, 68, 41-49.	12.2	16
42	Ventricular Septal Defect from Takotsubo Syndrome. Case Reports in Cardiology, 2016, 2016, 1-4.	0.2	6
43	New Management Strategies in Heart Failure. Circulation Research, 2016, 118, 480-495.	4.5	37
44	Heart Retransplant Recipients Have Better Survival With Concurrent Kidney Transplant Than With Heart Retransplant Alone. Journal of the American Heart Association, 2015, 4, .	3.7	13
45	Should Left Ventricular Assist Device Be Standard of Care for Patients With Refractory Heart Failure Who Are Not Transplantation Candidates?. Circulation, 2012, 126, 3088-3094.	1.6	7
46	The Year in Heart Failure. Journal of the American College of Cardiology, 2012, 60, 359-368.	2.8	19